Small-Cell Lung Cancer - Pipeline Review, H1 2016

Date: May 25, 2016
Pages: 645
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S33939464F9EN
Leaflet:

Download PDF Leaflet

Small-Cell Lung Cancer - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Small-Cell Lung Cancer - Pipeline Review, H1 2016’, provides an overview of the Small-Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
  • The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Small-Cell Lung Cancer Overview
Therapeutics Development
Small-Cell Lung Cancer - Therapeutics under Development by Companies
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
Small-Cell Lung Cancer - Pipeline Products Glance
Small-Cell Lung Cancer - Products under Development by Companies
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
Small-Cell Lung Cancer - Therapeutics Assessment
Drug Profiles
Small-Cell Lung Cancer - Recent Pipeline Updates
Small-Cell Lung Cancer - Dormant Projects
Small-Cell Lung Cancer - Discontinued Products
Small-Cell Lung Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Small-Cell Lung Cancer, H1 2016
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2016
Small-Cell Lung Cancer - Pipeline by 4SC AG, H1 2016
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2016
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2016
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2016
Small-Cell Lung Cancer - Pipeline by BeiGene, Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Bionomics Limited, H1 2016
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2016
Small-Cell Lung Cancer - Pipeline by Cellceutix Corporation, H1 2016
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2016
Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2016
Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by G1 Therapeutics, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Genzyme Corporation, H1 2016
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2016
Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Incyte Corporation, H1 2016
Small-Cell Lung Cancer - Pipeline by Ipsen S.A., H1 2016
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2016
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2016
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2016
Small-Cell Lung Cancer - Pipeline by Medivation, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2016
Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2016
Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2016
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2016
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Onxeo SA, H1 2016
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2016
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H1 2016
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by SciTech Development, LLC , H1 2016
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H1 2016
Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
Small-Cell Lung Cancer - Pipeline by ViiV Healthcare Limited, H1 2016
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2016
Small-Cell Lung Cancer - Dormant Projects, H1 2016
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2016
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2016
Small-Cell Lung Cancer - Dormant Projects (Contd..3), H1 2016
Small-Cell Lung Cancer - Dormant Projects (Contd..4), H1 2016
Small-Cell Lung Cancer - Dormant Projects (Contd..5), H1 2016
Small-Cell Lung Cancer - Dormant Projects (Contd..6), H1 2016
Small-Cell Lung Cancer - Discontinued Products, H1 2016
Small-Cell Lung Cancer - Discontinued Products (Contd..1), H1 2016


LIST OF FIGURES

Number of Products under Development for Small-Cell Lung Cancer, H1 2016
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

COMPANIES MENTIONED

4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc.
Alchemia Limited
Amgen Inc.
Andarix Pharmaceuticals, Inc.
Aposense Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BeiGene, Ltd.
BIND Therapeutics, Inc.
BioLineRx, Ltd.
Bionomics Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CellAct Pharma GmbH
Cellceutix Corporation
Cerulean Pharma, Inc.
Cornerstone Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
CytRx Corporation
Double Bond Pharmaceutical International AB
Eli Lilly and Company
Exelixis, Inc.
G1 Therapeutics, Inc.
Genzyme Corporation
GlaxoSmithKline Plc
Horizon Pharma Plc
Hutchison MediPharma Limited
Immunomedics, Inc.
Incyte Corporation
Ipsen S.A.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lindis Biotech GmbH
MabVax Therapeutics Holdings, Inc.
MedImmune, LLC
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
MolMed S.p.A.
Mologen AG
NanoSmart Pharmaceuticals, Inc.
Nektar Therapeutics
Nippon Kayaku Co., Ltd.
Novartis AG
Omnitura Therapeutics Inc.
OncoMed Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Oxford BioTherapeutics Ltd
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
SciTech Development, LLC
Spectrum Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synta Pharmaceuticals Corp.
Syros Pharmaceuticals, Inc.
Tarveda Therapeutics, Inc.
Tesaro, Inc.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Incorporated
ViiV Healthcare Limited
Zensun (Shanghai) Sci & Tech Co., Ltd.
Skip to top


Ask Your Question

Small-Cell Lung Cancer - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: